MedTrace Logo

Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year

NCT01365455 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 738

Last updated 2021-01-05

Study results available
· View outcomes & findings →

Summary

This study will assess the safety and efficacy of secukinumab compared to placebo in patients that have moderate to severe, chronic, plaque-type psoriasis.

Conditions

  • Moderate to Severe Plaque-type Psoriasis

Interventions

DRUG

secukinumab 150 mg

secukinumab (AIN457) 150mg or 300mg subcutaneous

DRUG

placebo to secukinumab 150 mg

Placebo to Match secukinumab (AIN457) 150mg or 300mg subcutaneous

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

  • Novartis Pharmceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2013-04-30
Completion
2013-04-30

Countries

  • United States
  • Argentina
  • Canada
  • Colombia
  • Estonia
  • Iceland
  • Israel
  • Japan
  • Latvia
  • Lithuania
  • Mexico
  • Taiwan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01365455 on ClinicalTrials.gov